G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and refreshing, especially for those of you who, like us, took an extended break to connect with ancient observances. Now, of course, the time has come to resume the usual routine of meetings, deadlines and the like. So tap your inner zen, grab a cup of stimulation, and dive into the tidbits below. Have a smashing day and, as always, do stay in touch …

The credibility of an expert witness for the U.K. pharmaceuticals industry was shot down by the National Institute for Health and Care Excellence in a legal row over pricing, The Times reports. The cost watchdog dismissed evidence from drug makers as “plainly not independent.” Through their trade group, the companies are seeking an unprecedented judicial review in an attempt to stop NICE from imposing fresh limits on prices for new drugs and reversing changes to the cost assessment of treatments for rare diseases.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.